Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Incidence of cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), infections and cardiovascular events across different chimeric antigen receptor (CAR) T-cell therapy products in large B-cell lymphoma (DLBCL): A nationwide analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

HMHimil MahadeviaKMKarnav ModiRSRaj Shah

Discussion

Loading...

Member takes

Overview

Retrospective analysis reveals incidence of cytokine release syndrome and other adverse events in CAR T-cell therapies for DLBCL informs treatment choices.

Key Points

  • This research aims to analyze the incidence of adverse events related to various CAR T-cell therapy products in DLBCL patients.
  • Retrospective study based on the 2022 National Inpatient Sample database.
  • Identified hospitalizations for DLBCL using ICD-10-CM codes.
  • Compared adverse events incidence using Pearson's chi-square and multivariate logistic regression.
  • Identified 1440 patients with DLBCL; therapy responses varied across CAR T-cell products.
  • Kymriah showed lower incidence of cytokine release syndrome compared to Yescarta.
  • Breyanzi exhibited lower rates of immune effector cell-associated neurotoxicity syndrome than Yescarta.

Cite This Study

Mahadevia et al. (2025) studied this question.

synapsesocial.com/papers/69362f5d4fa91c937236dc3ehttps://doi.org/10.1182/blood-2025-8012
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Inpatient CAR-T safety in the United States: Severe ICANS and CRS by donor source and antigen target (NIS 2022–2023).2026
  2. 2Comparative CRS risk across CAR-T constructs in DLBCL in real-world cohorts2025 · 1 citations
  3. 3Comparative inpatient outcomes among FDA-approved chimeric antigen receptor T-cell products: An analysis of the 2023 National Inpatient Sample.2026
  4. 4Adverse Events of CD19- and BCMA-Directed Chimeric Antigen Receptor T-Cell Therapy: An Analysis of the FDA Adverse Events Database2026
  5. 5Beyond the trial: Real-world CRS, icans, and healthcare burden of CAR T-cell therapy across US oncology practices2025 · 1 citations